<?xml version="1.0" encoding="UTF-8"?>
<ref id="b15-idmm-26-e5">
 <label>15.</label>
 <element-citation publication-type="webpage">
  <collab>US Food and Drug Administration</collab>
  <article-title>Drug Approval Package. TAMIFLU (oseltamivir phosphate) 30, 45 and 75 mg capsules and TAMIFLU (oseltamivir phosphate) 6 mg/mL powder for oral suspension</article-title>
  <comment>&lt;
   <ext-link ext-link-type="uri" xlink:href="www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062_tamiflu_toc.cfm" xmlns:xlink="http://www.w3.org/1999/xlink">www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062_tamiflu_toc.cfm</ext-link>&gt; (Accessed January 13, 2015).
  </comment>
 </element-citation>
</ref>
